Regulating Factors of PrPres Glycosylation in Creutzfeldt-Jakob Disease - Implications for the Dissemination and the Diagnosis of Human Prion Strains by Levavasseur, Etienne et al.
Regulating Factors of PrP
res Glycosylation in Creutzfeldt-
Jakob Disease - Implications for the Dissemination and
the Diagnosis of Human Prion Strains
Etienne Levavasseur
1, Isabelle Laffont-Proust
1,E ´milie Morain
1, Baptiste A. Faucheux
1,2, Nicolas Privat
1,
Katell Peoc’h
4,V e ´ronique Sazdovitch
1,2, Jean-Philippe Brandel
1, Jean-Jacques Hauw
2,3, Ste ´phane
Haı ¨k
1,2,3*
1INSERM, Avenir Team - Human Prion Diseases, Paris, France, 2APHP, R. Escourolle Neuropathology Laboratory, Paris, France, 3InVS, French National Center of Reference
for Unconventional Transmissible Agents, Paris, France, 4Biochemistry and Molecular Biology Department, Lariboisie `re Hospital, Paris, France
Abstract
Objective: The glycoprofile of pathological prion protein (PrP
res) is widely used as a diagnosis marker in Creutzfeldt-Jakob
disease (CJD) and is thought to vary in a strain-specific manner. However, that the same glycoprofile of PrP
res always
accumulates in the whole brain of one individual has been questioned. We aimed to determine whether and how PrP
res
glycosylation is regulated in the brain of patients with sporadic and variant Creutzfeldt-Jakob disease.
Methods: PrP
res glycoprofiles in four brain regions from 134 patients with sporadic or variant CJD were analyzed as a
function of the genotype at codon 129 of PRNP and the Western blot type of PrP
res.
Results: The regional distribution of PrP
res glycoforms within one individual was heterogeneous in sporadic but not in
variant CJD. PrP
res glycoforms ratio significantly correlated with the genotype at codon 129 of the prion protein gene and
the Western blot type of PrP
res in a region-specific manner. In some cases of sCJD, the glycoprofile of thalamic PrP
res was
undistinguishable from that observed in variant CJD.
Interpretation: Regulations leading to variations of PrP
res pattern between brain regions in sCJD patients, involving host
genotype and Western blot type of PrP
res may contribute to the specific brain targeting of prion strains and have direct
implications for the diagnosis of the different forms of CJD.
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Introduction
Human prion diseases are fatal neurodegenerative diseases.
They are clinically characterized by progressive dementia
associated with various neurological symptoms and neuropatho-
logically by spongiosis, gliosis and neuronal loss in the brain. An
almost constant biochemical hallmark is the accumulation of an
abnormal partially protease-resistant isoform (PrP
res) of the host-
encoded cellular prion protein (PrP
c). According to the protein
only hypothesis, the mechanism for prion propagation is thought
to involve the conversion of PrP
c into PrP
res [1,2]. In humans,
prion disorders occur in acquired, inherited and sporadic forms.
Sporadic Creutzfeldt-Jakob disease (sCJD) accounts for more than
80 percent of the cases [3]. Among sCJD patients, a wide range of
clinical and neuropathological phenotypes is observed. Recently,
efforts have focused on the molecular basis of such phenotypical
diversity considering the biochemical properties of PrP
res and the
presence of polymorphisms within the gene encoding PrP (PRNP).
Indeed, a classification of PrP
res Western blot patterns, obtained
after proteinase K (PK) digestion which leads to PK-resistant core
fragments of either 21 kDa (type 1) or 19 kDa (type 2), has been
proposed [4]. This difference results from distinct PK cleavage
sites of PrP
res [5]. Another contribution to the sCJD heterogeneity
is the methionine/ valine polymorphism at the codon 129 of PRNP
[6]. By correlating codon 129 genotypes and PrP
res types to
clinical and pathological features in a series of 300 sporadic CJD,
six molecular combinations corresponding to some phenotypic
variants were identified [7]. However, these observations are based
on the postulate that the same PrP conformer accumulates in the
whole brain [8]. This has been recently questioned since more
than one PrP
res type in the brain from sCJD patients has been
observed [9]. Human prion protein has two sites of N-
glycosylation at residues 181 and 197 [10]. Depending on the
occupation of these sites, different glycoforms are identified on
Western blot, the proportion of which may vary between prion
strains. For example, a higher amount of diglycosylated PrP
res
(type 2B) distinguishes vCJD from sCJD patients [8]. This
particular pattern is retained when the type 2B prion strain is
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2786transmitted from one species to another. This contributed to the
identification of the BSE as the origin of vCJD epidemics in
humans, suggesting that protein glycosylation may be part of
specific strain properties [11]. Glycosylation seems also to be
involved in the targeting of brain regions by prions leading to
strain-specific lesion profiles as previously suggested in a study
using transgenic mice overexpressing hamster PrP mutated at the
2
nd glycosylation site [12]. Other results recently obtained using
gene-targeted mice showed also that N-linked glycosylation of the
prion protein influences lesion profile and plaque occurrence
induced by some experimental strains of scrapie [13]. While PrP
res
glycosylation is a key factor in strain diagnosis and probably brain
targeting in human diseases, whether it is regulated between brain
regions, and how, remains largely unknown.
Hence, we analyzed the pattern of PrP
res glycosylation from
four different brain regions in a large series of 134 patients with
CJD and investigated how brain region, PRNP genotype at codon
129 and PrP
res type may affect the accumulation of PrP
res
glycotypes.
Results
Classification of CJD cases
Using results from Western blot typing of PrP
res and PRNP
genotyping, we obtained a distribution of the different molecular
subtypes of sCJD cases with a predominance of MM1 and VV2
patients (Fig 1 and Table 1), consistent with the distribution
reported by Head et al. in a UK population [8]. All the patients
with vCJD were methionine homozygotes and had type 2B PrP
res.
Regional variations of PrP
res glycoform ratio in sCJD
patients
Frontal cortex versus occipital cortex. No difference was
observed between these two regions as illustrated on Fig 2A, left
panel. The three glycoforms were evenly distributed in both
regions. The proportion of di- and nonglycosylated forms in the
frontal cortex correlated well with those observed in the occipital
cortex (regression analysis: r=0,58) (Fig 2A, right panel).
Frontal or occipital cortex versus thalamus. PrP
res
glycoform ratios from the frontal cortex and the thalamus were
not statistically different. However, they differed significantly
between the occipital cortex and the thalamus, which showed
more diglycosylated forms than the occipital cortex (Fig 2B).
Frontal or occipital cortex versus cerebellum. Compared
to the frontal and the occipital isocortices, a higher proportion of
monoglycosylated forms was found in the cerebellum (Fig 2C).
Frontal cortex exhibited more diglycosylated and nonglycosylated
forms than the cerebellum.
Cerebellum versus thalamus. Higher amounts of
diglycosylated forms were detected in the thalamus while an
increased accumulation of monoglycosylated forms occurred in
the cerebellum (Fig 2D).
Regional variations of PrP
res glycoform ratio in vCJD
patients
In the 11 French vCJD patients that we studied, we consistently
observed the typical type 2B PrP
res profile whithout any significant
difference between brain regions.
Influence of the PrP genotype at codon 129 on PrP
res
glycoform ratio
MM genotype. A significant increase of monoglycosylated
forms was observed in the frontal cortex (Fig 3A, 3B), occipital
cortex (Fig S1A, S1B), thalamus (Fig S2A, S2B) and cerebellum
(Fig S3A, S3B), compared to MV and VV genotypes.
MV genotype. Frontal cortex (Fig 3A, 3C), occipital cortex
(Fig S1A, S1C), thalamus (Fig S2A, S2C) and cerebellum (Fig S3A,
S3C) from MV cases accumulated significantly more
nonglycosylated forms than MM and VV cases.
VV genotype. In the frontal cortex (Fig 3B, 3C), thalamus
(Fig S2B, S2C) and cerebellum (Fig S3C) from VV patients,
diglycosylated forms were significantly more abundant compared
to MV patients and MM patients.
Therefore, a tendency was observed for each genotype to favour
the accumulation of one glycoform in the frontal cortex, the
occipital cortex, the thalamus and, to a lesser extent, in the
cerebellum. Valine homozygosity favoured the diglycosylated
form, methionine homozygosity favoured the monoglycosylated
form, and heterozygosity favoured the nonglycosylated form.
Influence of the PrP
res type on glycoform diversity
We found that the type of PrP
res affected the pattern of PrP
res
glycosylation in the thalamus, while little or no effect was detected
in the other studied brain regions. Two distinct populations
corresponding to MV1 and MV2 subgroups were evidenced.
Subgroup MV2 had more diglycosylated forms and subgroup
MV1 presented more nonglycosylated forms (Fig 4).
In addition, the homogeneity of PrP
res glycoform pattern
between regions dramatically varies depending on PrP
res types.
Indeed, regression analysis demonstrated r values equal to or
Figure 1. Western blot of PrP
res in different brain regions of a
patient with sporadic Creutzfeldt-Jakob disease using the 3F4
reference antibody. Type of PrP
res in frontal cortex (F), occipital
cortex (O), thalamus (T) and cerebellum (C) was determined using type
1, type 2A and type 2B standards after PK digestion.
doi:10.1371/journal.pone.0002786.g001
Table 1. Description of sporadic and variant Creutzfeldt-
Jakob disease populations.
Type MM MV VV Total
sCJD
Type 1 70 (56,9) 8 (6,5) 1 (0,8) 79 (64,2)
Type 2A 3 (2,4) 18 (14,6) 23 (18,7) 44 (35,8)
Total 73 (59,4) 26 (21,8) 24 (19,5) 123 (100)
vCJD
Type 2B 11 (100) 0 0 11 (100)
Number of sporadic CJD (sCJD) cases and variant CJD (vCJD) cases are
distributed according to the genotype at codon 129 of PRNP (MM: methionine
homozygote, VV: valine homozygote, MV: methionine-valine heterozygote) and
PrP
res type (type 1, type 2A or type 2B). Absolute numbers of cases are indicated
and the percentage of total is shown in round brackets.
doi:10.1371/journal.pone.0002786.t001
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PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2786Figure 3. Influence of PRNP codon 129 genotype on PrP
res glycoform ratios in the frontal cortex from sCJD patients. Each dot represents
one brain area from a patient and is defined on the ternary plot by three coordinates corresponding to the relative intensity of di-, mono- and
nonglycosylated bands. More monoglycosylated forms were detected in methionine homozygote patients compared to other genotypes (A, B).
Methionine/ valine heterozygote patients showed more nonglycosylated forms (A, C). Valine homozygote patients had more diglycosylated forms (B, C).
doi:10.1371/journal.pone.0002786.g003
Figure 2. Regional variations of PrP
res glycoforms in brains from sCJD patients. PrP
res glycoform ratios from the frontal and occipital cortex
were not statistically different (A, left panel). Each dot represents one brain area from a patient and is defined on the ternary plot by three coordinates
corresponding to the relative intensity of di-, mono- and nonglycosylated bands. The correlation between diglycosylated forms from these two
regions is shown on the regression curve (A, right panel). The thalamus exhibited more diglycosylated forms and less nonglycosylated forms than the
occipital cortex (B). The cerebellum exhibited more monoglycosylated forms than the cortical regions (C). More diglycosylated forms were also
detected in the thalamus when compared with the cerebellum, which showed more monoglycosylated forms (D).
doi:10.1371/journal.pone.0002786.g002
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diglycosylated form ratio between regions, while r values from
MV2 group ranged from 0,43 to 0,52 (Fig 5B, 5D, 5F). These
lower correlations indicate a greater heterogeneity between
glycoform ratio from different brain regions.
Discussion
This study provides new insight into the analysis of PrP
res
heterogeneity within sCJD cases, based upon the biochemical
analysis of at least 3 different brain regions from 123 sCJD cases.
This large series of sCJD tissues allowed us to identify the diversity
of PrP
res glycoforms within sporadic CJD forms and to establish a
correlation with PRNP genotype, brain region and Western blot
type of PrP
res. Our results demonstrate that the regional
distribution of PrP
res glycoforms within one individual is
heterogeneous in the sporadic form of CJD and suggest the
involvement of precise regulating mechanisms.
Different factors may contribute to this regulation. In the
normal brain of human, hamster and mouse, PrP
c glycosylation
pattern is submitted to a regional diversity [14,15,16]. In infected
human brains, the diversity of PrP
res glycoprofiles may result from
such a regional variation of the substrate for prion replication.
According to the prion hypothesis, this mechanism suggests that
the glycoprofile of PrP
c influences the glycoform ratio of PrP
res in
the conversion process. In acellular models of PrP conversion
indeed, the use of PrP
c with modified glycoforms ratio partially
modifies the glycosylation pattern of newly formed PrP
res [17]. In
the present study, we observed that the genotype at codon 129 of
PRNP influenced the glycoform ratio of PrP
res in a region
dependent manner. This raises the possibility that the regional
glycosylation state of PrP
c may be affected by PRNP polymor-
Figure 4. Influence of the PrP
res type on PrP
res glycoforms in the thalamus. Each dot represents one brain area from a patient and is defined
on the ternary plot by three coordinates corresponding to the relative intensity of di-, mono- and nonglycosylated bands. To rule out any codon
effect, the influence of PrP
res type was assessed in MV1 and MV2 patients. These two populations are almost separated on the ternary plot. A higher
content of diglycosylated forms is observed in the heterozygote MV2 subgroup compared to the MV1 subgroup.
doi:10.1371/journal.pone.0002786.g004
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res type on PrP
res glycoforms. A strong correlation is observed between diglycoforms of type 1 PrP
res from
different brain regions (r values equal to or above 0.80) (A, C, E). On the contrary, the glycoform ratio varies to a larger extent when patient had type 2
PrP
res (r values equal to or below 0.52) (B, D, F).
doi:10.1371/journal.pone.0002786.g005
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normal human brain.
Several studies have pointed out a relation between PrP amino
acid sequence (i.e. PRNP genotype) and PrP
res glycosylation in
inherited diseases associated to mutation located close to (D178N,
V180I, T183A, E200K) or remote (P102L) from the N-
glycosylation sites [18,19]. Whether the presence of a mutation
may modify the glycoform ratio of PrP
c in the human brain is
poorly documented. However we previously showed that in
patients with the V180I mutation, no diglycosylated PrP
res is
produced, while PrP
c glycosylation is normally processed [20].
This clearly indicates that additional factors, different from the
glycosylation state of PrP
c, may influence the glycoform ratio of
the accumulated PrP
res in the pathological condition.
Type 1 or type 2 PrP
res are thought to correspond to distinct
accessibilities of proteinase K to cleavage sites resulting from
different conformations of PrP
res. A diversity of glycotypes has
been described for type 2 PrP
res, linked to the various forms of the
diseases (sporadic, variant CJD, familial fatal insomnia). In
sporadic CJD patients with the same genotype at codon 129, we
found that PrP
res type markedly influences the glycoform ratio of
the accumulated PrP
res in definite brain regions. This suggests that
some conformers are more prone to convert distinct glycoforms of
PrP
c in sporadic diseases and that this phenomenon is regionally
regulated. In addition, to explain the strain mutation phenome-
non, it has been recently proposed that a single strain may consist
of an ensemble of molecular species containing a dominant PrP
res
type [21]. Such conformers may differ by the glycoform species
they favor during replication. It can be speculated that regional
factors influence the selection of PrP
res subpopulations leading to
the variation of the glycoform ratio that we finally detected.
The regional variation of PrP
res glycoform ratio demonstrated
in this study may be of interest in the understanding of ‘‘lesion
profile’’ and brain targeting by different prion strains. The
mechanisms that favor the accumulation of a given strain in a
given brain region are not known, but the regulation of PrPc/
PrP
res glycosylation is likely involved in this process [12,13,22]. As
a matter of fact, we found in sCJD cases that the thalamus favored
the production of type 2 PrP
res presenting a high content in
diglycosylated forms. It is noteworthy that besides sCJD, vCJD
and FFI are associated with a high content of diglycosylated forms
and are characterized by a ‘‘targeting’’ of the thalamus. In all
studied brain areas from French vCJD patients, as already
reported in the U.K. cases, we observed that the glycoform ratio
was remarkably constant. In this infectious form of prion disorders,
the pathogenic events are initiated by an exogenous PrP
res from
contaminated bovine tissues with its own defined characteristics,
such as a high glysosylated content that is maintained through
interspecies transmission. By contrast, the causative event in sCJD
is thought to be a rare, spontaneous and endogenous conversion of
the host-encoded PrP
c into PrP
res. The diversity of glycoform
ratios that we observed in sCJD may reflect the regulation of an
endogenous phenomenon by various host factors (genotype, brain
region) that may be overwhelmed in the case of an infection by a
virulent prion strain such as the bovine agent in vCJD patients.
Our observation of PrP
res glycoprofile diversity in sCJD raises
the question of the strain diagnosis based on biochemical PrP
res
analysis. The type 2B PrP
res profile is widely used as a diagnosis
marker of definite vCJD that until now has been observed in MM
patients only. However, in some VV2 CJD patients, the high
proportion of diglycosylated PrP
res we observed in the thalamus
was undistinguishable from the PrP
res profile detected in vCJD
cases. Studies using transgenic mice expressing human PrP suggest
that clinicopathological and biochemical presentations of BSE
infection may vary in humans with the genotype at codon 129 [23].
One possible explanation of our findings in these particular VV2
cases could be BSE infection (i.e. vCJD) in valine homozygote
patients. However, the mean age at death (.65 years, except one
case who was 27) and the neuropathological pattern (absence of
florid plaques) do not support such hypothesis. While the first MM
vCJD patients occurred simultaneously in UK and France, the
peak of French vCJD epidemics occurred in 2002 more than 5
years later than in the UK. Comparison of the 1980–1995 pattern
of BSE exposition in the UK and France indicated that it peaked
also later in France [24]. This probably explains the different
temporal pattern of vCJD incidence. We analyzed retrospectively
whether some French VV2 CJD patients who died between 1993
and 1999 exhibited also a thalamic PrP
res profile with high
glycosylation site occupancy similar to what is observed in vCJD.
The same profile of PrP
res ressembling type 2B could also be
detected in patients who died during the 1993–1999 period (Fig 6).
This suggests that these VV patients had indeed a genuine sporadic
disease rather than an atypical vCJD, which is very unlikely to have
occurred in an unrelated genotype and before 1996 in France.
Finally, the present work evidences regulations that lead to
highly significant variations of PrP
res pattern between brain
regions in sCJD patients, involving host genotype and Western
blot type of PrP
res as recapitulated in figure 7. These may
contribute to the specific brain targeting of prion strains and have
some diagnosis implications.
Methods
Case and tissue selection
This study was performed on patients referred to the French
National Surveillance Network for CJD during the period january
2000 to march 2007 and for which clinical, genetic and
neuropathological data were available to support a diagnosis of
definite sCJD [25]. Only patients with at least three available
regions out of the four studied (frontal cortex, occipital cortex,
thalamus and cerebellar vermis) were considered. Patients with
familial and iatrogenic CJD were excluded from the study. We
included 123 sCJD cases (103 patients had 4 available regions), 55
male and 68 female subjects, and the mean age at death was 68
(range, 24–90 years). In addition, a group of 11 french vCJD cases
was also studied, comprising of 4 male and 7 female subjects. The
mean age at death was 36 (range, 20–58 years). The patients’
relatives gave written informed consent for autopsy, and the study
was designed in accordance with the relevant French legislation.
PRNP analysis
DNA was extracted from buffy coat fraction of peripheral blood
after obtaining written informed consent from patients. Codon 129
polymorphism of the PRNP gene and the absence of mutation or
insertion was determined as described elsewhere [26].
Biochemical analysis of PrP
res
Frozen tissue was stored at 280uC. Brains were homogenized at
20% (w/v) using a Ribolyser (Bio-Rad) in 5% sterile glucose. One
volume of a 20% NaCl solution and one volume of a detergent
solution (20% sarkosyl, 2% SB3-14 and Tris 20 mM pH 7.4) were
added to one volume of 20% brain homogenate. This mixture had
a final pH of 7.6 and was digested with proteinase K at 10 mg/ml
(diluted in Tris-HCl 50 mM pH 8, CaCl2 1 mM) for 1 h at 37uC.
PrP
res was then purified by centrifugation at 27500 g for 2 h at
room temperature on 20% sucrose cushion, according to the
scrapie-associated fibril (SAF) protocol reported previously with
slight modifications [27]. Samples were subjected to a 12% Tris-
Prion Protein Diversity in CJD
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2786glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Proteins were electroblotted onto nitrocellulose
membrane. PrP staining was performed using anti-PrP monoclonal
antibody 3F4, epitope 109–112 of human PrP sequence (Signet,
MA, USA) at a dilution of 1 to 50000, and chemiluminescence
(ECL; RPN-2209; Amersham Biosciences, Freiburg, Germany) for
the detection of peroxidase activity [28]. Goat anti-mouse secondary
antibody horseradish peroxidase conjugated used was from Pierce
Biotechnology (31430, Rockford, IL) and used at a dilution of 1 to
5000. Quantitation of PrP
res glycoforms was performed using a GS-
800 calibrated densitometer and dedicated Quantity One software
(Bio-Rad Laboratories) as described [8]. Values for all PrP
res bands
weremeasuredonblotswitha non-saturatedsignalandcalculatedas
a percentage of the total PrP
res. When necessary, additional blots
were performed with serially diluted samples to obtain a signal in a
linearrange. Type 1 PrP
res and type 2 PrP
res werecharacterized by a
nonglycosylated band migrating at 21 kDa and at 19 kDa,
respectively, as described by Parchi et al. [6]. Typical standards of
type 1, type 2A and type 2B PrP
res were systematically included to
facilitate Western blot typing of PrP
res. Molecular weights were
determined using a protein standard (Novex Sharp Standard,
Invitrogen). Cases of sCJD were classified according to Parchi et al.
thatidentified six molecular subtypeson the basis ofthePRNP codon
129polymorphismandPrP
restype[7].CasesofsCJDforwhichboth
types of PrP
res were detected using 3F4 antibody in a same brain
region or in different regions were excluded from the study [8,9,29].
Statistical analysis
Linear regression, correlation and non parametric tests were
carried out using StatView v4.0 (Abacus Concepts, Berkeley, CA).
A p value of less than 0.05 was considered to be statistically
significant. Glycoform ratios were visualized on ternary plot as
originally described by Glatzel et al. [30]. Automated graphical
representations were generated using JMP software v6.0.0 (SAS).
Supporting Information
Figure S1 Influence of PRNP codon 129 genotype on PrP
res
glycoform ratios in the occipital cortex from sCJD patients. This
brain region was less affected by genotype than the frontal cortex
and the thalamus. However, methionine homozygote patients
Figure 7. Schematic representation of regulation of PrP
res
glycoforms by regional and molecular factors in sporadic
Creutzfeldt-Jakob disease. Arrows indicate which glycoform of
PrP
res is favored by individual factors. As an example, the accumulation
of diglycosylated PrP
res is favored in the thalamus, in VV patients and in
case of type 2 PrP
res.
doi:10.1371/journal.pone.0002786.g007
Figure 6. Similar PrP
res glycoform ratios with high glycosylation site occupancy in thalamus from VV2 sCJD patients and vCJD
patients. Each dot represents one brain area from a patient and is defined on the ternary plot by three coordinates corresponding to the relative
intensity of di-, mono- and nonglycosylated bands. We compared the VV2 patients from our sCJD series and vCJD patients with VV2 sCJD patients
who died before or just after the first variant breakout in 1996. No difference was observed between VV2 patients from the 2000–2007 series and VV2
patients from the period 1993–1999.
doi:10.1371/journal.pone.0002786.g006
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valine heterozygote patients were associated with a predominance
of nonglycosylated forms (A, C).
Found at: doi:10.1371/journal.pone.0002786.s001 (3.75 MB TIF)
Figure S2 Influence of PRNP codon 129 genotype on PrP
res
glycoform ratios in the thalamus from sCJD patients. Marked
differences were observed in this brain region. More monoglycosy-
lated forms were detected in methionine homozygote patients
compared to other genotypes (A, B,). Methionine/ valine heterozy-
gote patients presented more nonglycosylated forms (A, C). Valine
homozygote patients had more diglycosylated forms (B, C).
Found at: doi:10.1371/journal.pone.0002786.s002 (3.81 MB TIF)
Figure S3 Influence of PRNP codon 129 genotype on PrP
res
glycoform ratios in the cerebellum from sCJD patients. Like the
occipital cortex, this brain region was less affected by genotype
than the frontal cortex and the thalamus. However, methionine
homozygote patients remained associated with more monoglyco-
sylated forms (A, B), methionine/ valine heterozygote patients
were associated with a predominance of nonglycosylated forms (A,
C), while valine homozygote patients clearly presented more
diglycosylated forms (B, C).
Found at: doi:10.1371/journal.pone.0002786.s003 (3.81 MB TIF)
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